Background
Evidence-based guidelines from the American Thyroid Association (ATA) Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Revision of 2009 ATA guidelines covering risk stratification, surgery, radioiodine (RAI), TSH suppression, EBRT, and surveillance for thyroid nodules and differentiated thyroid cancer (DTC: papillary, follicular). 133-page document.
Interventions and follow up
Document type: 2015 ATA management guidelines for adult DTC; evidence graded by ACP system
Primary endpoint: Consensus recommendations on diagnosis, surgery, RAI, RT, surveillance
mFollow up: Not applicable
Primary endpoint: Consensus recommendations on diagnosis, surgery, RAI, RT, surveillance
mFollow up: Not applicable
Results
Risk stratification: ATA low/intermediate/high risk guides RAI use, TSH suppression intensity, and surveillance
Low-risk DTC: Lobectomy acceptable; RAI not routinely recommended; modest TSH suppression
EBRT role: Limited; considered for gross extrathyroidal extension not completely resected, or selected unresectable local disease
Low-risk DTC: Lobectomy acceptable; RAI not routinely recommended; modest TSH suppression
EBRT role: Limited; considered for gross extrathyroidal extension not completely resected, or selected unresectable local disease
Adverse events
Type: Guidelines document
Toxicity: Adverse events discussed per individual treatment modality, not as trial outcomes
Toxicity: Adverse events discussed per individual treatment modality, not as trial outcomes
Conclusions
The 2015 ATA guidelines provide a comprehensive, risk-stratified framework for thyroid nodules and DTC, emphasizing individualized de-escalation for low-risk disease and targeted intensification for high-risk patients. EBRT plays only a limited role.
Key Limitations
Guideline (consensus) document, not a trial; many recommendations rest on low-quality or expert-opinion evidence; rapidly evolving molecular and surgical practice may outpace recommendations.
Clinical Context
Widely adopted reference standard for DTC management. From a radiation oncology standpoint, EBRT is reserved for incompletely resected gross extrathyroidal extension or unresectable disease, not routine adjuvant use. Complements AHNS EBRT guidance (Kiess 2016).